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In oropharyngeal squamous cell carcinoma (OPSCC), the expression pattern of toll-like receptors (TLRs), in 
comparison between human papillomavirus (HPV)-positive and -negative tumors differs. TLRs control innate 
immune responses by activating, among others, the nuclear factor- (NF-) signaling pathway. Elevated NF-
 activity is detectable in several cancers and regulates cancer development and progression. We studied TLR5 
expression in 143 unselected consecutive OPSCC tumors, and its relation to HPV-DNA and p16 status, 
clinicopathological parameters, and patient outcome, and studied TLR5 stimulation and consecutive NF-B 
cascade activation in vitro in two human OPSCC cell lines and immortalized human keratinocytes (HaCat). 
Clinicopathological data came from hospital registries, and TLR5 immunoexpression was evaluated by 
immunohistochemistry. Flagellin served to stimulate TLR5 in cultured cells, followed by analysis of the activity 
of the NF-B signaling cascade with In-Cell Western for I and p-I. 
High TLR5 expression was associated with poor disease-specific survival in HPV-positive OPSCC, which 
typically shows low TLR5 immunoexpression. High TLR5 immunoexpression was more common in HPV-
negative OPSCC, known for its less-favorable prognosis. In vitro, we detected NF- cascade activation in the 
HPV-positive OPSCC cell line and in HaCat cells, but not in the HPV-negative OPSCC cell line.  
Our results suggest that elevated TLR5 immunoexpression may be related to reduced NF- activity in HPV-
negative OPSCC. The possible prognosis-worsening mechanisms among these high-risk OPSCC patients 



















DSS  Disease-specific survival 
DAMP  danger-associated molecular pattern 
HPV  Human papillomavirus 
HNSCC Head and neck squamous cell carcinoma 
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p-I   phosphorylated form of I protein 
NF-  Nuclear factor- 
OPSCC Oropharyngeal squamous cell carcinoma 
PAMP  pathogen-associated molecular pattern 
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SCC  Squamous cell carcinoma 
TLR  Toll-like receptor 
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According to the latest WHO classification of head and neck tumors, the oropharyngeal squamous cell 
carcinoma (OPSCC) that is associated with human papillomavirus (HPV) and the HPV-unrelated OPSCC are 
distinct entities (El-Naggar et al., 2017). Incidence of HPV-positive OPSCC is increasing (Nichols et al., 2013; 
Rietbergen et al., 2013; Chaturvedi et al., 2011; Ang et al., 2010; Nasman et al., 2009; Gillison et al., 2000), 
whereas incidence of HPV-negative OPSCC has remained stable or has declined (Chaturvedi et al., 2011; 
Nasman et al., 2009). Patients with HPV-positive OPSCC have a more favorable prognosis than do those with 
OPSCC that is HPV-negative (Ang et al., 2010; Gillison et al., 2000). Differences between these two OPSCC 
have been under intense study for their underlying mechanisms involved in carcinogenesis and tumor behavior, 
and ultimately to allow the design of targeted OPSCC-prevention, -diagnostic, and -treatment strategies. 
Toll-like receptors (TLRs) participate in the initiation of innate immune cascades by recognizing pathogen-
associated molecular patterns (PAMPs) of bacteria, viruses, fungi, and parasites, and endogenous danger-
associated molecular patterns (DAMPs) in cells that are damaged or dying (Kawai and Akira 2005; Matzinger 
2002; Janeway 1989). Activation of TLRs may promote carcinogenesis, yet other reports suggest anti-tumor 
responses and a role in halting tumor progression (Basith et al., 2012; Ioannou and Voulgarelis 2010). TLRs may 
be prognostic in several cancers including colorectal-, salivary gland-, and squamous cell carcinoma of the 
tongue and non-small cell lung cancer (Makinen et al., 2015; Korvala et al., 2014; Zhou et al., 2014; Kauppila et 
al., 2013; Grimm et al., 2010). In OPSCC, expression patterns of TLR5, 7, and 9 between HPV-positive and 
HPV-negative tumors differ (Jouhi et al., 2015). Recently, prognostic values have been proposed for TLR5 and 7 
in HPV-positive OPSCC (Jouhi et al., 2017). 
TLR activation by PAMPs or by DAMPs leads to activation of nuclear factor- (NF-), a key transcription 
factor involved in the inflammatory pathway. NF- integrates multiple stress stimuli and regulates innate and 
adaptive immune responses during inflammation and during cancer development and progression (Karin et al., 
2002; Balkwill and Mantovani 2001). It influences cancer initiation, promotion, and progression by enhancing 
cancer cell proliferation (Luo et al., 2004), preventing apoptosis (Van Antwerp et al., 1996), and by improving 













activity is detectable in breast cancer (Chua et al., 2007), melanoma (Yang et al., 2007), colon cancer (Scartozzi 
et al., 2007), multiple myeloma (Annunziata et al., 2007), pancreatic cancer (Weichert et al., 2007), and lung 
cancer (Tew et al., 2008).  
Inactive NF- is localized in the cytosol, complexed with an inhibitory protein belonging to the Ifamily 
(Baeuerle and Baltimore 1988b; Baeuerle and Baltimore 1988a). Initiation of NF- activation occurs by 
degradation of the IB protein of the NF- complex by IB kinase (IKK) (Beg et al., 1993; Shirakawa and 
Mizel 1989). IB-protein degradation leads to activation of NF- and release of a short-lived phosphorylated 
form of I protein (p-I) that will eventually be degraded in the proteasome (Beg et al., 1993). Activated NF-
 then enters the nucleus, initiating gene activation as a fast response to a stimulus such as TLR activation by 
PAMP or DAMP (Baeuerle and Baltimore 1988b; Baeuerle and Baltimore 1988a). According to Ludde et al. 
(2007), elimination of NF- activity in mouse hepatocytes resulted in elevated inflammatory cytokine 
expression and spontaneous carcinogenesis suggesting a tumor suppressor role for NF- (Luedde et al., 2007). 
Liu et al. (2006), on the other hand, observed reduced immunoexpression of IKK-α as paralleling the increasing 
aggressiveness of human skin squamous cell carcinoma (SCC) when evaluated by SCC grade (Liu et al., 2006). 
Maeda et al. saw IKK-α to be less strongly expressed in oral carcinomas than in normal oral epithelium (Maeda 
et al., 2007).   
We aimed to investigate TLR5 expression, its relation to HPV-DNA and p16 status, clinical parameters, and 
patient outcome in vivo in 143 unselected consecutive OPSCC patients. Furthermore, we studied flagellin-
induced TLR5 stimulation and consecutive NF-B-cascade activation in vitro in two human OPSCC lines and in 
immortalized human keratinocytes. 
 
 













Patients and clinicopathological data 
The patient cohort, as described in part elsewhere (Carpen et al., 2018; Carpen et al., 2017), included 143 of 224 
consecutive patients diagnosed with a primary OPSCC between February 2012 and May 2016 at Helsinki 
University Hospital, Finland. Inclusion criteria for the study were available tumor HPV-DNA PCR and 
p16
INK4a
(p16) status, and availability as a tissue microarray (TMA) block. Excluded were patients with palliative 
treatment. Clinicopathological data: age, sex, tumor histology, grade, UICC 8
th
 edition TNM stage (Brierley et 
al., 2017), primary treatment, and patient outcome and status at last follow-up, we manually recorded from 
hospital registries. Patients were in two categories: having treatment by surgery followed by chemoradiotherapy 
called Sx + C(RT) or having only chemoradiotherapy C(RT). Their follow-up scheme has been described earlier 
(Carpen et al., 2018). This study received the approval of the Research Ethics Board of the Hospital District of 
Helsinki and Uusimaa, with institutional permission granted. 
For evaluation purposes, the data classification was as proposed by Smeets et al. into an HPV-positive group of 
89 that included only p16-positive and HPV-DNA-positive samples, and an HPV-negative group that included 
18 p16-positive but HPV-DNA-negative samples, 33 p16-negative HPV-DNA-negative samples, and 3 p16-
negative but HPV-DNA-positive samples (Table 1) (Smeets et al., 2007). The data reflect the current reported 
characteristics for HPV-related and non-related OPSCC according to the latest TNM 8 classification (Nauta et 
al., 2018; Gillison 2016; Gillison et al., 2008).  
 
Immunohistochemistry 
Tissue-microarray (TMA) -blocks were prepared and slides were stained by immunohistochemistry as described 
(Makinen et al., 2012).  For expression of TLR5 in the tumor TMA samples, the immunohistochemical staining 
















Two of the authors (J.H. and A.K.K.) scored independently the decoded TMA blocks immunostained with the 
TLR5 antibody. Any discordance in scoring was solved by reassessment to achieve consensus. TLR scoring was 
based on intensity of positivity in the tumor tissue as described (Jouhi et al., 2015). Scoring of TLR5, present on 
the plasma membrane and in the cytoplasm, was on the scale: none (0), mild (1), moderate (2), strong (3). If 
several tumor spots were available for analysis, our choice was the highest TLR5 positivity value. 
 
Cell culture 
Cell-culture experiments involved two human OPSCC lines UT-SCC-65 and UT-SCC-69 (Department of 
Otorhinolaryngology-Head and Neck Surgery, University of Turku, Finland), and the immortalized human 
keratinocyte cell line HaCaT. Earlier we had evaluated p16 immunoexpression and HPV-DNA PCR targeting 
the E6/E7 region from pelleted UT-SCC-65 and UT-SCC-69 cells (Jouhi et al., 2015). In the UT-SCC-65 cell 
line, p16 status was negative, but HPV-DNA status was positive. In UT-SCC 69, both p16 status and HPV-DNA 
status were positive. However, a recent study investigated HPV-DNA in UT-SCC-65 by PCR and described it as 
HPV negative (Lepikhova et al., 2018). Thus, based on an algorithm suggested by Smeets et al. (Smeets et al., 
2007), and findings of Lepikhova et al. (Lepikhova et al., 2018), we considered UT-SCC-65 to be HPV negative. 
The UT-SCC cells were cultured at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5g/l 
glucose, supplemented with 10% fetal calf serum (FCS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), non-essential amino acids (NEAA), glutamine, penicillin, and streptomycin. The HaCat cells were 
cultured at 37°C in DMEM medium containing 1.0g/l glucose with 5% FCS, penicillin, streptomycin, 













Waltham, MA, USA), glutamine from Lonza (Lonza Group AG, Basel, Switzerland), and all other cell culture 
reagents from Sigma-Aldrich, (Merck KGaA, Darmstadt, Germany). 
 
In-Cell Western 
Cells on 96-well plates were stimulated with 100 ng/ml flagellin (FLA) (InvivoGen, San Diego, CA, USA) for 
15-120 minutes. Thereafter, the cells were fixed with 2% paraformaldehyde (PFA) for 20 min, and 
permeabilized with 0.1% Triton X-100 in PBS for 10 min. Cells were treated with Odyssey Blocking buffer 
(LI-COR Biosciences, Lincoln, NE, USA) for 30 min, followed by incubation with mouse-anti phospho-I p-
IgG (Cell Signaling Technology, Leiden, Netherlands, dilution 1:200) or rabbit-anti I IgG (Cell 
Signaling Technology, dilution 1:50). Subsequently, the cells were incubated with IRDye 800 donkey anti-
mouse or anti-rabbit IgGs and nuclear marker DRAQ-5 (Thermo Fisher Scientific), which served for 
normalization. Detection and quantification of the signal was performed on three parallel samples with Odyssey 
Infrared Imager and software (LI-COR Biosciences). The experiment was repeated three times and the results 
were calculated as an average of the three parallel samples in the three experiments.  
 
Statistical analysis 
SPSS version 25.0 (IBM SPSS Statistics, IBM Corporation, New York, NY, USA) was utilized for statistical 
analysis. The cross-tabulation of categorical variables was performed using Chi-square with an asymptotic or an 
exact P-value when most suitable. Disease-specific survival (DSS) rates were calculated by Kaplan-Meier (KM) 
estimate. Evaluation of statistical significance in the KM analysis utilized log-rank test. Follow-up time in the 
DSS was defined as the period between the last treatment day and the last day of follow-up, or date of death 
from the disease. The Cox proportional hazards model served in univariate and multivariable survival analysis. 













assumption was tested with KM curves. An independent t-test served for comparison of mean values of 
continuous data between categorical groups with two classes.   
The relative signal values in the cell culture experiments are presented as mean ±SD. Students t-test (Microsoft 
Inc., Redmond, WA, USA) served to determine the significance of the relative signal of I and p-I at 





TLR5 immunoexpression and its association with patient and tumor characteristics 
TLR5 was expressed in 94 (65.7%) of the OPSCC and was associated with HPV status (P=0.018) (Table 1). 
High TLR5 immunoexpression more often occurred in the HPV-negative OPSCC.  
TLR5 was associated with N class, tumor site, and tumor grade (Table 2). The proportion of N0-grade OPSCC 
among patients with high TLR5 immunoexpression was higher (P=0.008). Regardless of TLR5 
immunoexpression level, the tonsils dominated as the primary tumor site. Proportionally higher TLR5 
immunoexpression was also related to a primary tumor site other than the tonsils, namely the base of the tongue, 
the soft palate, or the posterior wall of the oropharynx (P=0.006). Proportionally higher TLR5 
immunoexpression was associated with grade-1 and -2 tumors than with grade-3 tumors (P=0.004).  
 
TLR5 immunoexpression and its association with survival 
For the survival analysis, TLR5 immunoexpression was dichotomized into low (immunoscore 0-1) and high 













with low TLR5 immunoscores (94.7%) (P=0.006). In HPV-positive OPSCC that typically shows low TLR5 
immunoexpression, patients with high TLR5 immunoexpression had poorer DSS (85.3%) than did those with 
low TLR5 immunoexpression, at 98.2%, (P=0.024). The HPV-negative subgroup showed no statistically 
significant association between DSS and TLR5 immunoexpression (Figure 1). 
 
TLR5 as an independent prognostic factor in HPV-positive subgroups 
In the multivariable analysis of all 143 patients, TLR5 immunoexpression was not an independent prognostic 
factor (P=0.141) (Table 3). Although TLR5 had no significant interaction with HPV status (P=0.116), stratifying 
the analysis according to HPV status was considered clinically justified. 
Among HPV-positive OPSCC patients, high TLR5 immunoexpression was an independent prognostic factor for 
poor DSS (P=0.028). No other factors showed independent statistical significance for DSS among HPV-positive 
patients (Table 3). Among HPV-negative patients, no factors independently influenced the DSS. 
 
NF-  cascade activationin vitro by stimulation of TLR5 
The results of our in vivo studies on the role of TLR5 in OPSCC led us to study the possible mechanisms 
involved in vitro.  In cell culture experiments, we stimulated the TLR5 receptor with flagellin and measured the 
expression level of the negative regulator of the NF- signaling cascade, namely Inhibitor of the and 
its inactive phosphorylated form p-NF- activation is preceded by a phosphorylation of to p-
(Beg et al., 1993; Shirakawa and Mizel 1989), giving us the means to qualitatively evaluate TLR5 activation 
of the NF-B signaling cascade by quantitative changes in  and in p- expressions.  
The expression of TLR5, NF-Iandp-I in vitro were qualitatively confirmable in the immunoblotting 













and HaCat cells (data not shown). The TLR5 stimulation with flagellin led to a decreased amountofin 
HaCaT cells during the first 30 minutes (at 0, and at 15-, and 30-min timepoints). At the 60-min and 120-min 
timepoints,  then increased, exceeding the amount measured at 0 minutes. In the HPV-positive OPSCC cell 
line UT-SCC-69,  decreased during the first 60 minutes of incubation (at 0, 15-, 30-, and 60-minute 
timepoints) and returned to its initial level in 120 minutes. No statistically significant decrease in was 
detectable in the stimulated HPV-negative OPSCC cell line UT-SCC-65 cultivation at any of the timepoints 
during the 120-minute follow-up (Figure 2A). No significant changes occurred in the amount of p-
following flagellin stimulation in any of the cell lines studied (Figure 2B). In the HaCat cells and in the 
HPV-positive OPSCC cell line UT-SCC-69 the amount of p-relative to p-increased during 
the first 30 and 60 minutes of incubation, respectively, and then returned to its initial level or below in 120 
minutes. In HPV-negative OPSCC cell line UT-SCC-65 there was no statistically significant change in the 




This study shows that TLR5 stimulation with flagellin did not activate NF- signaling in HPV-negative 
OPSCC, that typically has high TLR5 expression. In addition, this study provides further evidence for TLR5 
expression as being an independent prognostic biomarker in HPV-positive OPSCC. Our results from 
multivariable analysis indicate that TLR5 expression was not an independent prognostic factor among all 143 
patients. However, high TLR5 expression was an independent indicator of poor DSS in those with HPV-positive 
OPSCC. The association of high TLR5 expression and poor DSS among HPV-positive OPSCC patients 
validates our earlier observation for the p16-positive and the HPV-DNA-positive patients (Jouhi et al., 2017). As 
in our earlier retrospective patient series, TLR5 immunoexpression appeared not to be prognostic in HPV-













TLRs, having both tumorigenic and antitumorigenic effects, participate in immunomodulation of the tumor 
microenvironment. Activation of the TLRs by PAMPs derived from microbes, and by DAMPs derived from 
injured and necrotic cancer cells, leads to a release of cytokines and chemokines by the activated cells. TLRs 
expressed in the immune cells contribute to chronic inflammation and an attack against tumor cells, whereas 
TLRs expressed during carcinogenesis by tumor cells are proposed to promote cancer-cell survival and 
chemoresistance (Basith et al., 2012). A worsening effect of high TLR5 expression on prognosis is supported by 
the finding of increased TLR5 expression in association with a higher mortality rate and disease recurrence in 
oral mobile-tongue squamous cell carcinoma (SCC) (Kauppila et al., 2013). A similar association also occurs for 
progression of cervical neoplasia and carcinogenesis of the stomach and colon (Pimentel-Nunes et al., 2013; 
Pimentel-Nunes et al., 2012; DeCarlo et al., 2012; Kim et al., 2008). Contradictory findings also exist: low TLR5 
expression predicting a poor prognosis in oral mobile-tongue squamous cell carcinoma (SCC) (Makinen et al., 
2015), whereas high expression of TLR5 correlates with good prognosis in non-small cell lung cancer (Zhou et 
al., 2014). 
High TLR5 immunoexpression was more common in the HPV-negative OPSCC.  Our earlier study showed that 
strong Treponema denticola-specific protease (Td-CTLP) immunoexpression was associated with high TLR5 
expression and low TLR 7 expression in the HPV-DNA-negative OPSCC, and that strong Td-CTLP 
immunoexpression was associated with a poor DSS. Interestingly, strong immunoexpression of Td-CTLP 
occurred mainly among the HPV-DNA-negative tumors (Kylma et al., 2018). This led us to study the prognostic 
role of TLR5 in the current patient series and its possible functional role in vitro involved with HPV-positive and 
–negative OPSCC cell lines.  
In cell culture experiments on HPV-positive and HPV-negative OPSCC cell lines, we studied phosphorylation of 
to p-followed by TLR5 stimulation with flagellin, to evaluate the level of NF-B signaling cascade 
activation. Typically, p- expression is higher after treatment of cells with various inducers, and then rapidly 
decreases following its degradation in a proteasome (Beg et al., 1993). Re-accumulation of the inactive NF--













et al., 1993). We did not detect any difference in the total amount of p-I in any of the cell lines studied after 
stimulation with flagellin. However, we observed an increase in the ratio of p-I to I at early time points in 
the HaCat cells and in the HPV-positive OPSCC cell line UT-SCC-69 following stimulation of TLR5 with 
flagellin. This indicates activation of the NF- cascade. The amount of p-I to I then returned to its initial 
level in a 120-minute incubation, which may be related to Ia gene expression as has been proposed by de 
Martin et al. (de Martin et al., 1993). As there were no statistically significant changes in the amount of p-I to 
Iin the HPV-negative OPSCC cell line UT-SCC-65, we propose that the NF--cascade was not activated by 
TLR5 stimulation with flagellin in this cell line. 
Our earlier study has shown that TLR5 expression level is higher in the HPV-negative cell line UT-SCC-65, than 
in the HPV-positive cell line UT-SCC-69  reflecting the in vivo TLR5 immunoexpression data (Jouhi et al., 
2015). 
Based on our results, it is impossible to deduce whether any relationship exists between elevated TLR5 
expression and failure to activate NF- cascade in the HPV-negative OPSCC cell line. Further studies with 
HPV positive and negative OPSCC cell lines with both low and high level of TLR5 expression could give more 
information on this matter. However, in an earlier study on Salmonella flagellin in intestinal epithelial cells, 
Tallant et al. (2004) showed that among several cancerous and non-cancerous cell lines, some had an abundance 
of TLR5 protein and yet showed poor or no NF- activation by flagellin. They proposed that this may be due 
to intracellular location of TLR5, TLR5 gene mutation, or lack of required TLR5 co-receptor or adaptor (Tallant 
et al., 2004). Earlier, we detected TLR5 immunoexpression both in plasma membrane and in cytoplasm in 
OPSCC. The localization was independent of HPV status proposing that the localization may not be the cause of 
missing NF- cascade activation by flagellin (Jouhi et al., 2015). Higher TLR5 expression and loss of NF- 
cascade activation by TLR5 stimulation may, on the other hand, be linked to generally poorer patient outcome in 
HPV-negative OPSCC. This is supported by the observation that NF- cascade activation prevents the 













Recently, evidence shows that those patients with HPV-positive OPSCC and intratumoral HPV-specific type I–
polarized T cells have an improved response to standard therapy (Welters et al., 2018). Other research has 
detected a high level of CD8+ tumor-infiltrating lymphocytes in the HPV-positive OPSCC with low TLR5 
immunoexpression (Haeggblom et al., 2019).  Furthermore, in a mouse model, stimulation of the TLR5 by 
flagellin had a radioprotective effect on the non-tumor cells, and yet did not influence tumor-cell radiosensitivity 
(Burdelya et al., 2008). We may hypothesize that the cytokine response to TLR5 stimulation by flagellin in the 
HPV-positive versus the HPV-negative OPSCC differs. We may also speculate that TLR5 stimulation of the 
HPV-negative OPSCC leads to activation of a signaling pathway other than the NF- pathway. Tan et al. on 
the other hand, have discussed cross-talk between several pattern recognition receptors (PRRs) sharing 
overlapping ligand specificities, and immune processes requiring activation of several PRRs to achieve non-
additive responses (Tan et al., 2014). It may be, that in addition to TLR5, activation of another PRR is required 
for effective activation of NF- cascade in the HPV-negative OPSCC.  
In the HPV-positive cell line and in HaCat cells, that serve in our study as a model for non-cancerous epithelial 
cells, the NF- cascade was activated by stimulation of TLR5 with flagellin. It is well known that HPV-
positive OPSCCs have better prognosis than HPV-negative OPSCCs, and thus it is interesting that HPV-positive 
cell line behaves more like non-cancerous keratinocytes when stimulated with flagellin. This suggests that NF-
 activation may contribute to the more favorable prognosis of HPV-positive OPSCC patients, which is further 
supported by the observation that TLR5 activation suppresses tumor cell proliferation and progression in human 
breast cancer (Cai et al., 2011). Yet, another study failed to link activation of TLR5 by flagellin to tumor 
progression in an oral SCC cell line showing strong expression of TLR5, 7, and 9 (Park et al., 2010). An adverse 
effect from TLR5 activation has also been detectable in salivary gland adenocarcinoma and in gastric carcinoma, 
in both of which such activation caused cancer progression (Park et al., 2011; Song et al., 2011).  
We consider that our results are applicable to OPSCC patients outside the current patient series because the 
clinicopathological characteristics of our patients with either an HPV-positive or HPV-negative tumor are in line 













al., 2008). However, as patients with HPV-positive OPSCC typically have a better prognosis, the low number of 
events reduced the power of our survival analysis, as we have suggested earlier (Haeggblom et al., 2019; Jouhi et 
al., 2017). In addition, expression levels of immune cells or cytokines were not investigated here and call for 
further investigation.  
We studied TLR5 immunoexpression and patient outcome in vivo and TLR5 stimulation response in vitro, which 
limits the interpretation of our results to these factors only. The association of high TLR5 expression and poor 
DSS among HPV-positive patients validates our earlier result (Jouhi et al., 2017), but does not claim any 
causality between them. However, our findings lead us to propose that HPV-positive and HPV-negative OPSCC 
cell lines differ in both their TLR5 expression level and in their TLR5 stimulation response, and that these 




Our results provide further evidence that high TLR5 expression may serve as a prognostic factor for poor 
disease-specific survival (DSS) in HPV-positive OPSCC. This finding is consistent with our previous findings 
(Jouhi et al., 2017). Furthermore, in vitro stimulation of TLR5 with flagellin activated the NF- cascade in 
HPV-positive OPSCC cells and in HaCat cells, whereas no activation of the NF- cascade in HPV-negative 
OPSCC cells occurred. Elevated TLR5 immunoexpression in HPV-negative OPSCC may be related to missing 
activation of NF- cascade, and the possible prognosis-worsening mechanisms among these high-risk OPSCC 
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Table 1 Patient and tumor characteristics; age, sex, smoking and alcohol consumption, T class (primary tumor size), N 
class (presence of regional lymph node metastasis), tumor stage, tumor site of origin, grade of differentiation, treatment 
(Sx + (C)RT = surgery + chemoradiotherapy, C(RT) = chemoradiotherapy), toll-like receptor (TLR) 5 
immunoexpression stratified according to human papilloma virus (HPV) status. 
N = 143 
HPV-positive *)         
(n = 89) 
HPV-negative **)                  
(n = 54) P Missing 
Age at diagnosis 60.8 (mean) 62.2 (mean) 
  Sex 
    Male  73 (82.0) 37 (68.5) 
  Female 16 (18.0) 17 (31.5) 0.063 0 
Smoking 
    Never 32 (36.0) 9 (16.7) 
  Earlier 37 (41.6) 7 (13.0) 
  Current 20 (22.5) 38 (70.4) < 0.001 0 
Excess alcohol 
consumption 
    Never 49 (72.1) 21 (41.2) 
  Earlier 6 (8.8) 10 (19.6) 
  Currently 13 (19.1) 20 (39.2) 0.003 24 
T class 
    T1-T2 58 (65.2) 36 (66.7) 
  T3-T4 31 (34.8) 18 (33.3) 0.855 0 
N class 
    N0 9 (10.1) 16 (29.6) 
  N1-N3 80 (89.9) 38 (70.4) 0.004 0 
Tumor stage  
    I-II 72 (80.9) 27 (50.0) 
  III-IV 17 (19.1) 27 (50.0) < 0.001 0 
Tumor site 
    Tonsil 67 (75.3) 22 (40.7) 
  Base of tongue 21 (23.6) 14 (25.9) 
  Soft palate 1 (1.1) 13 (24.1) 
  Posterior wall of 
oropharynx 0 (0) 5 (9.3) < 0.001 0 
Tumor grade 
    1 0 (0) 3 (5.6) 
  2 7 (7.9) 18 (33.3) 
  3 82 (92.1) 33 (61.1) < 0.001 0 
Treatment 
    Sx ± (C)RT 33 (37.1) 21 (38.9) 
  (C)RT 56 (62.9) 33 (61.1) 0.829 0 
TLR 5 
    0 36 (40.4) 13 (24.1) 
  1 19 (21.3) 8 (14.8) 
  2 17 (19.1) 10 (18.5) 
  3 17 (19.1) 23 (42.6) 0.018 0 
 
Statistically significant P values bolded. 
*) HPV-positive = p16- and HPV-DNA-positive OPSCC 



























Table 2 Patient and tumor characteristics (as in Table 1) association with toll-like receptor (TLR) 5 
immunoexpression.  
  TLR 5     
N = 143 0 (n = 49) 1 (n = 27) 2 (n = 27) 3 (n = 40) P Missing 
Sex 
      Male  41 (83.7) 17 (63.0) 22 (81.5) 30 (75.0) 
  Female 8 (16.3) 10 (37.0) 5 (18.5) 10 (25.0) 0.202 0 
Smoking 
      Never 17 (34.7) 7 (25.9) 7 (25.9) 10 (25.0) 
  Earl ier 18 (36.7) 9 (33.3) 9 (33.3) 8 (20.0) 
  Current 14 (28.6) 11 (40.7) 11 (40.7) 22 (55.0) 0.327 0 
Excess  alcohol 
consumption 
      Never 25 (65.8) 14 (73.7) 12 (50.0) 19 (50.0) 
  Earl ier 6 (15.8) 0 (0) 5 (20.8) 5 (13.2) 
  Currently 7 (18.4) 5 (26.3) 7 (29.2) 14 (36.8) 0.246 24 
T class 
      T1-T2 33 (67.3) 20 (74.1) 20 (74.1) 21 (52.5) 
  T3-T4 16 (32.7) 7 (25.9) 7 (25.9) 19 (47.5) 0.184 0 
N class 
      N0 3 (6.1) 3 (11.1) 6 (22.2) 13 (32.5) 
  N1-N3 46 (93.9) 24 (88.9) 21 (77.8) 27 (67.5) 0.008 0 
Tumor s tage  
      I-I I  37 (75.5) 21 (77.8) 20 (74.1) 21 (52.5) 
  I I I-IV 12 (24.5) 6 (22.2) 7 (25.9) 19 (47.5) 0.061 0 
Tumor s ite 
      Tons il 35 (71.4) 21 (77.8) 14 (51.9) 19 (47.5) 
  Base of tongue 12 (24.5) 6 (22.2) 9 (33.3) 8 (20.0) 
  Soft pa late 1 (2.0) 0 (0) 3 (11.1) 10 (25.0) 
  Posterior wal l  of 
oropharynx 1 (2.0) 0 (0) 1 (3.7) 3 (7.5) 0.006 0 
Tumor grade 
      1 0 (0) 0 (0) 1 (3.7) 2 (5.0) 
  2 2 (4.1) 4 (14.8) 5 (18.5) 14 (35.0) 
  3 47 (95.9) 23 (85.2) 21 (77.8) 24 (60.0) 0.004 0 
Treatment 
      Sx ± (C)RT 22 (44.9) 11 (40.7) 9 (33.3) 12 (30.0) 
  (C)RT 27 (55.1) 16 (59.3) 18 (66.7) 28 (70.0) 0.491 0 
 















Table 3. Univariate and multivariable Cox regression analysis for Disease specific survival (DSS) in a series of all 143 
oropharyngeal squamous cell carcinoma (OPSCC) patients, including 89 human papilloma virus (HPV) -positive and 
54 HPV-negative OPSCC patients.  
 
Univariate analysis  Multivariabe analysis Multivariable analysis Multivariable analysis 
 
 
All patients (N = 143) All patients (N =143) HPV-positive *) (n = 89) HPV-negative **) (n = 54) 
  HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P 
Sex 
            Male vs female 1.3 0.5 - 3.7 0.596 
         Age at time of 










Earlier vs never 0.5 0.1 - 2.5 0.376 0.7 0.1 - 4.1 0.705 0.9 0.1 - 6.7 0.945 0.0 
 
0.982 
Currently vs never 2.3 0.8 - 7.2 0.143 2.0 0.6- 7.2 0.294 5.1 0.5 - 49.4 0.160 2.3 0.4 11.7 0.330 
T class 
            T3-4 vs T1-2 2.0 0.8 - 4.9 0.153 
         N class 
            N1-3 vs N0 3.6 0.5 - 26.9 0.215 
         Tumor stage 
            III-IV vs I-II 3.8 1.5 - 9.9 0.006 2.1 0.8-5.9 0.145 0.4 0.04 - 3.7 0.406 4.4 0.9-21.3 0.062 
Treatment 
            (C)RT vs Sx ± (C)RT 0.6 0.2 - 1.4 0.239 
         TLR 5 
             2-3 vs 0-1 4.2 1.4 - 12.8 0.011 2.5 0.8 - 8.1 0.129 14.2 1.3 - 151.1 0.028 0.9 0.2-3.6 0.906 
HPV status 
            HPV-negative vs    
HPV-positive 3.6 1.3 - 9.6 0.010 1.3 0.4 - 4.6 0.649 
       
T class (primary tumor size), N class (presence of regional lymph node metastasis), Sx + (C)RT (surgery + 
chemoradiotherapy), C(RT) (chemoradiotherapy), TLR5 (toll-like receptor 5 immunoexpression), HPV-positive (p16- 
and HPV-DNA-positive OPSCC), HPV-negative (p16-negative and HPV-DNA-positive or –negative OPSCC, and 













Figure 1. Disease-specific survival (DSS) curves for human papilloma virus (HPV) -positive and HPV-negative 






























Figure 2. Flagellin-induced changes in NF- signaling cascade in cell lines (HaCat, UT-SCC-65 and UT-SCC-69). 
Relative amount of relative amount of p-and relative p-Cexpressionpresented as 
function of time after TLR5 stimulation with flagellin. Nuclear marker DRAQ-5 served for normalization. * P < 0.05; 














Elevated TLR5 expression in vivo and loss of NF-  activation via TLR5 in vitro detected in HPV-negative 
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 High TLR5 expression was associated with poor disease-specific survival in HPV-positive OPSCC, which 
typically shows low TLR5 immunoexpression.  
 High TLR5 immunoexpression was more common in HPV-negative OPSCC, known for its less-favorable 
prognosis.  
 In vitro stimulation of TLR5 with flagellin activated the NF- cascade in HPV-positive OPSCC cells and in 
HaCat cells, whereas no activation of the NF- cascade in HPV-negative OPSCC cells occurred.  
 Our results suggest that elevated TLR5 immunoexpression may be related to reduced NF- activity in HPV-
negative OPSCC. The possible prognosis-worsening mechanisms among these high-risk OPSCC patients 
however, require further evaluation.  
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